Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01310530 · ClinicalTrials.gov registry record · NA

Partial Breast Proton Therapy for Early Stage Breast Cancer

A NA study of Breast Cancer, sponsored by Loma Linda University.

Active
Registry status
NA
Development phase
150
Enrollment target
2
Study locations

NCT01310530 is a NA study of Breast Cancer that is active but no longer recruiting, run by Loma Linda University. The registered enrollment target is 150 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01310530, a NA study of Breast Cancer, is active but no longer recruiting, sponsored by Loma Linda University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this is to determine the efficacy and toxicity of proton therapy when used to deliver partial breast radiotherapy in patients with early stage breast cancer with low or intermediate risk factors.

Conditions Studied

Interventions

  • RADIATION Proton Beam Radiotherapy

Study Locations (2)

California

  • Loma Linda University Medical Center / James M. Slater MD Proton Treatment Center / Department of Radiation Medicine / 11234 Anderson St. - Loma Linda
  • Loma Linda University Medical Center - Loma Linda

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2011-05-04
Est. Completion 2026-12
Phase NA

Sponsor

Loma Linda University

237 total trials

What the Registry Record Tells You About NCT01310530

The ClinicalTrials.gov registry entry for NCT01310530 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Proton Beam Radiotherapy is the first listed.

NCT01310530 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01310530 about?

NCT01310530 is a clinical study titled "Partial Breast Proton Therapy for Early Stage Breast Cancer". The purpose of this is to determine the efficacy and toxicity of proton therapy when used to deliver partial breast radiotherapy in patients with early stage breast cancer with low or intermediate risk factors.

What is the current status of trial NCT01310530?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2011-05-04. Estimated completion is 2026-12.

What conditions does trial NCT01310530 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT01310530?

The interventions under investigation include: Proton Beam Radiotherapy (RADIATION).

Who is sponsoring clinical trial NCT01310530?

This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01310530 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.